Generated: December 16, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 074290
« Back to Dashboard
, which is a drug marketed by Mylan, Accord Hlthcare, Fresenius Kabi Usa, Hospira, Mylan Labs Ltd, Pharmachemie Bv, Pierre Fabre, Teva Parenteral, Teva Pharms Usa, Watson Labs, Watson Labs Inc, and West-ward Pharms Int, and is included in fourteen NDAs. It is available from six suppliers. Additional details are available on the ETOPOSIDE profile page.
The generic ingredient in ETOPOSIDE is etoposide. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the etoposide profile page.
Summary for 074290
|Formulation / Manufacturing:||see details|
Pharmacology for NDA: 074290
Medical Subject Heading (MeSH) Categories for 074290
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Jul 17, 1995||TE:||AP||RLD:||No|
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.